Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Diabetic Retinopathy-Pipeline Review, H1 2015

Diabetic Retinopathy-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Diabetic Retinopathy-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Diabetic Retinopathy-Pipeline Review, H1 2015', provides an overview of the Diabetic Retinopathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Diabetic Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Diabetic Retinopathy Overview 8

Therapeutics Development 9

Pipeline Products for Diabetic Retinopathy-Overview 9

Pipeline Products for Diabetic Retinopathy-Comparative Analysis 10

Diabetic Retinopathy-Therapeutics under Development by Companies 11

Diabetic Retinopathy-Therapeutics under Investigation by Universities/Institutes 15

Diabetic Retinopathy-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Diabetic Retinopathy-Products under Development by Companies 18

Diabetic Retinopathy-Products under Investigation by Universities/Institutes 21

Diabetic Retinopathy-Companies Involved in Therapeutics Development 22

Acucela Inc. 22

Aerpio Therapeutics, Inc. 23

Angstrom Pharmaceuticals, Inc. 24

Antisense Therapeutics Limited 25

Aprogen, Inc. 26

BioDiem Ltd 27

Biomar Microbial Technologies 28

Charlesson LLC. 29

Crinetics Pharmaceuticals, Inc. 30

Dimerix Bioscience Pty Ltd 31

EyeGene, Inc. 32

Foresee Pharmaceuticals, LLC 33

GTx, Inc. 34

Icon Bioscience, Inc. 35

IMMD Inc. 36

Islet Sciences, Inc. 37

Kowa Company, Ltd. 38

LegoChem Biosciences, Inc 39

MacuCLEAR, Inc. 40

MingSight Pharmaceuticals 41

Molecular Design International, Inc. 42

OcuCure Therapeutics, Inc. 43

Ohr Pharmaceutical Inc. 44

PanOptica, Inc. 45

Promedior, Inc. 46

R-Tech Ueno, Ltd. 47

Resolvyx Pharmaceuticals, Inc 48

RestorGenex Corporation 49

Sirnaomics, Inc. 50

Stelic Institute & Co. 51

Stemedica Cell Technologies, Inc. 52

Targazyme, Inc. 53

ThromboGenics NV 54

TWi Pharmaceuticals, Inc. 55

Diabetic Retinopathy-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 60

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

49-B-Drug Profile 66

A-6-Drug Profile 68

A-717-Drug Profile 70

AC-301-Drug Profile 71

AKB-9778-Drug Profile 72

ALG-1001-Drug Profile 74

AP-202-Drug Profile 76

ATL-1103-Drug Profile 77

BDM-E-Drug Profile 79

Beta-LGND2-Drug Profile 81

CLT-01001-Drug Profile 83

CLT-01007-Drug Profile 84

CLT-01012-Drug Profile 85

cyclosporine-Drug Profile 86

Cyndacel-M-Drug Profile 87

DG-3173-Drug Profile 88

DMX-200-Drug Profile 90

Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy-Drug Profile 91

DT-23552-Drug Profile 92

E-1086-Drug Profile 93

EG-Mirotin-Drug Profile 94

emixustat hydrochloride-Drug Profile 96

FP-008-Drug Profile 98

IB-09A0133-Drug Profile 99

IMD-0354-Drug Profile 100

JP-153-Drug Profile 101

L-779976-Drug Profile 102

LCB-030110-Drug Profile 103

Lycium Anti-Angiogenic Proteoglycan-Drug Profile 104

MC-4001-Drug Profile 105

Mesenchymal Stem Cells-Drug Profile 106

MS-553-Drug Profile 108

OC-10X-Drug Profile 109

ocriplasmin (recombinant)-Drug Profile 110

OLX-302-Drug Profile 113

PAN-90806-Drug Profile 114

PRM-167-Drug Profile 115

Protein for Oncology, Ophthalmology and Metabolic Disorders-Drug Profile 116

Recombinant Protein for Cancer and Diabetic Retinopathy-Drug Profile 117

RES-529-Drug Profile 118

ripasudil-Drug Profile 120

RTU-007-Drug Profile 121

RTU-1096-Drug Profile 122

RX-20001-Drug Profile 123

squalamine lactate-Drug Profile 124

Stem Cell Therapy for Diabetic Retinopathy-Drug Profile 126

STNM-1510-Drug Profile 127

STP-601-Drug Profile 128

TZ-101-Drug Profile 129

V-1932-Drug Profile 131

Diabetic Retinopathy-Recent Pipeline Updates 132

Diabetic Retinopathy-Dormant Projects 159

Diabetic Retinopathy-Discontinued Products 164

Diabetic Retinopathy-Product Development Milestones 165

Featured News & Press Releases 165

Appendix 175

Methodology 175

Coverage 175

Secondary Research 175

Primary Research 175

Expert Panel Validation 175

Contact Us 175

Disclaimer 176

List of Tables

Number of Products under Development for Diabetic Retinopathy, H1 2015 13

Number of Products under Development for Diabetic Retinopathy-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 16

Number of Products under Development by Companies, H1 2015 (Contd..1) 17

Number of Products under Development by Companies, H1 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H1 2015 19

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Diabetic Retinopathy-Pipeline by Acucela Inc., H1 2015 26

Diabetic Retinopathy-Pipeline by Aerpio Therapeutics, Inc., H1 2015 27

Diabetic Retinopathy-Pipeline by Angstrom Pharmaceuticals, Inc., H1 2015 28

Diabetic Retinopathy-Pipeline by Antisense Therapeutics Limited, H1 2015 29

Diabetic Retinopathy-Pipeline by Aprogen, Inc., H1 2015 30

Diabetic Retinopathy-Pipeline by BioDiem Ltd, H1 2015 31

Diabetic Retinopathy-Pipeline by Biomar Microbial Technologies, H1 2015 32

Diabetic Retinopathy-Pipeline by Charlesson LLC., H1 2015 33

Diabetic Retinopathy-Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 34

Diabetic Retinopathy-Pipeline by Dimerix Bioscience Pty Ltd, H1 2015 35

Diabetic Retinopathy-Pipeline by EyeGene, Inc., H1 2015 36

Diabetic Retinopathy-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 37

Diabetic Retinopathy-Pipeline by GTx, Inc., H1 2015 38

Diabetic Retinopathy-Pipeline by Icon Bioscience, Inc., H1 2015 39

Diabetic Retinopathy-Pipeline by IMMD Inc., H1 2015 40

Diabetic Retinopathy-Pipeline by Islet Sciences, Inc., H1 2015 41

Diabetic Retinopathy-Pipeline by Kowa Company, Ltd., H1 2015 42

Diabetic Retinopathy-Pipeline by LegoChem Biosciences, Inc, H1 2015 43

Diabetic Retinopathy-Pipeline by MacuCLEAR, Inc., H1 2015 44

Diabetic Retinopathy-Pipeline by MingSight Pharmaceuticals, H1 2015 45

Diabetic Retinopathy-Pipeline by Molecular Design International, Inc., H1 2015 46

Diabetic Retinopathy-Pipeline by OcuCure Therapeutics, Inc., H1 2015 47

Diabetic Retinopathy-Pipeline by Ohr Pharmaceutical Inc., H1 2015 48

Diabetic Retinopathy-Pipeline by PanOptica, Inc., H1 2015 49

Diabetic Retinopathy-Pipeline by Promedior, Inc., H1 2015 50

Diabetic Retinopathy-Pipeline by R-Tech Ueno, Ltd., H1 2015 51

Diabetic Retinopathy-Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015 52

Diabetic Retinopathy-Pipeline by RestorGenex Corporation, H1 2015 53

Diabetic Retinopathy-Pipeline by Sirnaomics, Inc., H1 2015 54

Diabetic Retinopathy-Pipeline by Stelic Institute & Co., H1 2015 55

Diabetic Retinopathy-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 56

Diabetic Retinopathy-Pipeline by Targazyme, Inc., H1 2015 57

Diabetic Retinopathy-Pipeline by ThromboGenics NV, H1 2015 58

Diabetic Retinopathy-Pipeline by TWi Pharmaceuticals, Inc., H1 2015 59

Assessment by Monotherapy Products, H1 2015 60

Number of Products by Stage and Target, H1 2015 62

Number of Products by Stage and Mechanism of Action, H1 2015 65

Number of Products by Stage and Route of Administration, H1 2015 67

Number of Products by Stage and Molecule Type, H1 2015 69

Diabetic Retinopathy Therapeutics-Recent Pipeline Updates, H1 2015 136

Diabetic Retinopathy-Dormant Projects, H1 2015 163

Diabetic Retinopathy-Dormant Projects (Contd..1), H1 2015 164

Diabetic Retinopathy-Dormant Projects (Contd..2), H1 2015 165

Diabetic Retinopathy-Dormant Projects (Contd..3), H1 2015 166

Diabetic Retinopathy-Dormant Projects (Contd..4), H1 2015 167

Diabetic Retinopathy-Discontinued Products, H1 2015 168

List of Figures

Number of Products under Development for Diabetic Retinopathy, H1 2015 13

Number of Products under Development for Diabetic Retinopathy-Comparative Analysis, H1 2015 14

Number of Products under Development by Companies, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 20

Comparative Analysis by Early Stage Products, H1 2015 21

Assessment by Monotherapy Products, H1 2015 60

Number of Products by Top 10 Targets, H1 2015 61

Number of Products by Stage and Top 10 Targets, H1 2015 61

Number of Products by Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 64

Number of Products by Top 10 Routes of Administration, H1 2015 66

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 67

Number of Products by Top 10 Molecule Types, H1 2015 68

Number of Products by Stage and Top 10 Molecule Types, H1 2015 69

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Acucela Inc.

Aerpio Therapeutics, Inc.

Angstrom Pharmaceuticals, Inc.

Antisense Therapeutics Limited

Aprogen, Inc.

BioDiem Ltd

Biomar Microbial Technologies

Charlesson LLC.

Crinetics Pharmaceuticals, Inc.

Dimerix Bioscience Pty Ltd

EyeGene, Inc.

Foresee Pharmaceuticals, LLC

GTx, Inc.

Icon Bioscience, Inc.

IMMD Inc.

Islet Sciences, Inc.

Kowa Company, Ltd.

LegoChem Biosciences, Inc

MacuCLEAR, Inc.

MingSight Pharmaceuticals

Molecular Design International, Inc.

OcuCure Therapeutics, Inc.

Ohr Pharmaceutical Inc.

PanOptica, Inc.

Promedior, Inc.

R-Tech Ueno, Ltd.

Resolvyx Pharmaceuticals, Inc

RestorGenex Corporation

Sirnaomics, Inc.

Stelic Institute & Co.

Stemedica Cell Technologies, Inc.

Targazyme, Inc.

ThromboGenics NV

TWi Pharmaceuticals, Inc.

Diabetic Retinopathy Therapeutic Products under Development, Key Players in Diabetic Retinopathy Therapeutics, Diabetic Retinopathy Pipeline Overview, Diabetic Retinopathy Pipeline, Diabetic Retinopathy Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com